Psychedelics

Cannabis Update: New Hampshire Expands Medical Program, Alabama's Licensing Battles & More
Psychedelics Therapy For Military Veterans In MA, Clinical Research Of Psilocybin In AZ And More
Cresco Labs Co-Founder Comments On First Tranche Of $25M Financing Of Psychedelics-Focused REIT
Psychedelics Therapy For Military Veterans In MA, Clinical Research Of Psilocybin In AZ And More
Cresco Labs Co-Founder Comments On First Tranche Of $25M Financing Of Psychedelics-Focused REIT
Unlock Decades Of Meditation Benefits In Days With 40 Years Of Zen's New Ketamine-Assisted Program
American Medical Association Officially Endorses Drug Decriminalization: We Need 'Something That Actually Works'

Psychedelics Recent News

FDA Committee 'Completely Lost Sight Of The Big Picture' Says Retired Lieutenant General Urging Approval On MDMA For PTSD
New Milestone In Psychedelics Market: Canadian Start-Up Will Export Psilocybin And MDMA To Australia
Canada Magic Mushrooms and MDMA market is hitting new milestones as canada has licensed Optimi to export psilocybin and MDMA to Australia
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision.
Psychedelic-Assisted Therapy In Vermont, State-Run Model In New Hampshire And Medical Marijuana In Arkansas
Vermont Psychedelics And Harm Reduction Legislation
What's Going On With MindMed And Psychedelic Stocks?
Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD). Here's a look at what's moving psychedlic stocks:
FDA Panel Rejects MDMA Therapy For PTSD, Citing Concerns Over Research Data In Setback For Advocates
A committee of advisors to the U.S. Food and Drug Administration (FDA) dealt a blow to the burgeoning field of psychedelic medicine by recommending against the approval of MDMA-assisted therapy as a treatment for PTSD.
MDMA Therapy For PTSD Closer To Legality As Key FDA Approval Meeting Approaches, Sparking Hope And Controversy
MDMA nears FDA approval for PTSD treatment, sparking hope and controversy. Read now about its potential impact and the challenges ahead.
Imperial College Scientists Dose First Patient With 5-MeO-DMT To Examine One Of The Most Potent Psychedelics' Effects On The Brain
Unveiling Mayan Secrets: Hallucinogens In Ancient Ball Game Rituals
By Lucía Tedesco via El Planteo
Canadian Biotech Duo Hits Psilocybin Extraction Milestone For API Development At Scale
Red Light Holland and PharmAla achieve psilocybin extraction milestone, advancing API development for scalable medical products. Read now!
Top Federal Drug Official Praises Psychedelics' Potential, Psilocybin And Ketamine On City Health Plans And More
NIDA Director praises psychedelics, NCCIH highlights psilocybin's benefits and Atlanta explores adding psilocybin, ketamine to health plans.
Psychedelic Investing For Beginners: Seize The Golden Moment!
In recent years, the landscape of medicine and mental health has been rapidly evolving, with psychedelic therapies taking center stage. As an advocate and investor in the psychedelic space, I’m excited to share insights into what I believe is the dawn of a trillion-dollar industry.
Trump Vows To Commute Sentence Of Silk Road Founder Ross Ulbricht Amid Boos And Jeers At Libertarian Convention
In a speech before the Libertarian National Convention on Saturday night where Donald Trump was consistently booed and jeered, the former president promised to commute the sentence of Ross Ulbricht, the creator of the online illegal drug marketplace Silk Road.

Explore Benzinga's Financial Tools

Find Stocks Tailored to Your Trading Interests
Find Stocks Tailored to Your Trading Interests
Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Compare Benzinga's Favorite Stock Brokers

Claim Exclusive Offers

Compare Benzinga's Favorite Cryptocurrency Brokers

Claim Exclusive Offers